IMMUNOSTEM starts a Phase-I Clinical Trial in Honeymooners

IMMUNOSTEM technology refers to using a virus (specifically a lentivirus) to deliver a new gene into cells, which will then produce a specific protein PD-L1 (Programmed Death-Ligand 1). This protein plays a key role in the immune system by telling T-cells not to attack a specific other cell (in this case, beta cells). This is done to the patient's own blood. It is removed, treated in this way, and…